Information  X 
Enter a valid email address

Verseon Corporation (VERS)

  Print      Mail a friend

Tuesday 26 November, 2019

Verseon Corporation

Cancellation of Depositary Interests Facility

RNS Number : 6127U
Verseon Corporation
26 November 2019
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF THE MARKET ABUSE REGULATION (596/2014/EU) ("MAR").

November 26, 2019

 

Verseon Corporation

("Verseon" or the "Company")

 

Cancellation of Depositary Interests Facility

FREMONT, Calif.-Verseon Corporation (AIM:VERS), a clinical-stage pharmaceutical company, today announces that it will not maintain its depositary interests ("DIs") facility following the intended cancellation of the Company's AIM listing, which, subject to shareholder approval, is expected to take effect on December 19, 2019 (the "Cancellation"). In accordance with the terms of the DI trust deed, the Company has directed its depositary, Computershare Investor Services PLC ("Computershare"), to terminate the DIs with effect from December 30, 2019 (the "Effective Date"). Computershare will give notice of termination to all DI holders.

Tender of Common Shares to the Company

DI holders should note that prior to 1:00 p.m. GMT on December 9, 2019, any DI holder may elect to tender their respective holding of DIs pursuant to the procedures set out in the tender offer circular dated November 22, 2019.

All DIs remaining as at the Effective Date will be cancelled, DI holders will be entered as shareholders on the Company's share register, and share certificates will be issued to the holders of such Common Shares.

- Ends -

 

For further information, please contact

Verseon Corporation

www.verseon.com

Sebastian Wykeham / Tina Schlafly

+1 (510) 225 9000



Arden Partners (NOMAD and Broker)


Ruari McGirr / Ciaran Walsh / Dan Gee-Summons (Corporate Finance)

+44 (0) 20 7614 5900

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCLFFFFLTLEFIA

a d v e r t i s e m e n t